Allergy Therapeutics PLC Satellite Symposium at EAACI 2017 (3866I)
June 19 2017 - 2:00AM
UK Regulatory
TIDMAGY
RNS Number : 3866I
Allergy Therapeutics PLC
19 June 2017
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Group")
Allergy Therapeutics hosts satellite symposium at EAACI 2017
World-leading experts discuss allergy immunotherapies
Allergy Therapeutics (AIM:AGY), the fully integrated specialty
pharmaceutical company specialising in allergy vaccines, announces
today that a satellite symposium entitled: "The Best Therapies by
Design" was held at the 36(th) Annual Congress of the European
Academy of Allergy and Clinical Immunology (EAACI) in Helsinki,
Finland on 18 June 2017, providing an overview of the technologies
and strategies involved in designing the best immunotherapies.
Chaired by Professor Stephen Durham, four world-leading experts
in the field of allergy, pollen, and immunotherapy vaccine
delivery, Jörg Kleine-Tebbe, Erika Jensen-Jarolim, Uwe Berger &
Tim Higenbottam presented on the strategy, design and
considerations involved in creating immunotherapies such as Allergy
Therapeutics' flagship product, Pollinex Quattro(R). Uwe Berger and
Erika Jensen-Jarolim discussed the importance of highlighting
relevant allergens and characterising them sufficiently. Jörg
Kleine-Tebbe discussed why successful immunotherapy requires
identification of the optimal dose before Phase III studies are
begun, before Tim Higenbottam finished the session describing the
results recently gained from the Group's clinical studies.
Manuel Llobet, Chief Executive Officer, commented: "We are
delighted with our progress in developing the next generation of
allergen immunotherapy products. Our latest clinical data on
dose-ranging confirms that our unique allergen-specific
immunotherapies are formulated to the optimal strength and we
believe Allergy Therapeutics has the potential to transform allergy
treatment with optimised-dose, well-characterised, aluminium-free
products."
Satellite Symposium: "The Best Therapies by Design"
1. The importance of defining the optimal dose - Jörg
Kleine-Tebbe, Allergie und Asthma - Zentrum Westend, Berlin.
2. Molecular fingerprinting of complex allergoids - Erika
Jensen-Jarolim, Institute of Pathophysiology and Allergy Research,
Medical University Vienna.
3. Rationale for broad spectrum grass immunotherapy - Uwe
Berger, Medical University of Vienna. Head of Aerobiology &
Pollen Information Research Unit.
4. Defining the plateau of the efficacy for Allergen Specific
Immunotherapy - Tim Higenbottam, R&D Director, Allergy
Therapeutics.
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Finance Director
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley / Duncan Monteith, Corporate Finance
Tom Salvesen, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / Ivar Milligan
allergytherapeutics@consilium-comms.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international specialty
pharmaceutical company focussed on the treatment and diagnosis of
allergic disorders including immunotherapy vaccines that cure
disease. The Group sells proprietary products and third party
products from its subsidiaries in nine major European countries and
via distribution agreements in an additional ten countries.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics
is headquartered in Worthing, UK with MHRA-approved manufacturing
facilities. The Group employs c.495 employees and is listed on the
London Stock Exchange (AIM:AGY). For more information, please see
www.allergytherapeutics.com.
About the Annual Congress of the European Academy of Allergy and
Clinical Immunology (EAACI)
The EAACI Congress 2017 is a congress organised by the European
Academy of Allergy and Clinical Immunology (EAACI) which offers a
unique opportunity to learn about new discoveries and exchange
experience with professionals in the field of allergy and clinical
immunology. The Congress is taking place in Helsinki, Finland from
17-21 June 2017.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCSFWFIMFWSELM
(END) Dow Jones Newswires
June 19, 2017 02:00 ET (06:00 GMT)
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2023 to Apr 2024